



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Rd,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### Further US patent for Opal Biosciences' antimicrobial, BDM-I

Melbourne, 11 December 2015: BioDiem Ltd is pleased to announce that a further US patent has been granted and published for BDM-I.

The claims cover treatment of a range of infections including

- potentially life-threatening infections
  - caused by bacteria such as Methicillin-resistant *Staph aureus* (Golden Staph) and also *Mycobacterium tuberculosis* (TB) and *Streptococcus pneumoniae* and *Haemophilus influenza* which can cause serious infections, including such as systemic and respiratory infections;
  - caused by fungi such as *Candida albicans* and *glabrata*, and *Aspergillus fumigatus* among others; and
- common superficial infections caused by the fungi responsible for skin infections like tinea or athlete's foot.

These claims support the strategy of BioDiem's Opal Biosciences to develop treatments for serious infections, such as can occur in those patients recovering from cancer treatment where the immune system is weakened, and also a topical treatment (ointment/gel) for treatment of simpler infections of the skin.

BioDiem's subsidiary, Opal Biosciences Ltd is conducting a capital-raising to continue the development of

- an injectable product, Opal-I, which will be targeted to the treatment of serious infections including those which are antibiotic-resistant; and
- a treatment for the skin, Opal-T, for superficial infections.

BDM-I is also currently in US programs for drug-resistant tuberculosis (TB), the fungal infection caused by *Pneumocystis*, and a biowarfare agent.

- ENDS -

### **About BioDiem Ltd**

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit [www.biodiem.com](http://www.biodiem.com).

### **About Opal Biosciences Ltd**

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of our products:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to the skin.

For more information, please visit [www.opalbiosciences.com](http://www.opalbiosciences.com).